AliveDx Submits 510(k) Notification for MosaiQ AiPlex CD
The MosaiQ AiPlex CD is designed to significantly enhance the accuracy and speed of celiac disease diagnosis while streamlining laboratory processes. This innovative approach aims to empower healthcare providers with faster diagnostic capabilities.
Overview of the MosaiQ AiPlex CD Multiplex Assay
AliveDx has officially submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its MosaiQ AiPlex Celiac Disease (CD) microarray. This multiplex assay is set to revolutionize how celiac disease is diagnosed by enabling a syndromic approach. Receiving IVDR-CE mark certification highlights the assay's capabilities in simplifying serological evaluations and providing actionable insights for clinicians.
The Importance of Celiac Disease Diagnosis
Celiac disease is a serious chronic autoimmune condition affecting millions worldwide. It primarily targets the small intestine and is associated with a wide range of symptoms that can affect multiple organ systems. For individuals who are genetically predisposed, the consumption of gluten induces an abnormal immune response, leading to the production of harmful autoantibodies and consequential intestinal damage.
MosaiQ AiPlex CD: Features and Benefits
The MosaiQ AiPlex CD multiplex assay provides a comprehensive analysis using just a small sample of 20 ?l. By combining both IgA and IgG isotypes, this assay enhances the sensitivity and specificity of celiac disease diagnostics. It incorporates five key markers identified in clinical guidelines, allowing for simultaneous detection and analysis.
Accelerating Diagnosis to Enhance Patient Care
Manuel O. Méndez, CEO of AliveDx, expressed excitement over the submission, underscoring the potential of the MosaiQ AiPlex CD to drastically reduce the time it takes to diagnose celiac disease, which can often exceed four years. By enabling rapid identification of relevant markers, this assay promises to facilitate early diagnosis and improve treatment intervention, thus offering significant relief to affected patients.
Advantages of the MosaiQ Solution
Designed for efficiency, the MosaiQ solution offers fast results with a seamless workflow. By consolidating multiple test markers into a single assay, it provides vital insights that help clinicians make informed decisions sooner. With the capability to rapidly analyze up to 425 disease markers in one hour, the system reduces hands-on time significantly and minimizes the likelihood of manual errors.
About AliveDx
AliveDx is focused on harnessing innovative diagnostic insights to transform patient care and foster advancements in healthcare. With decades of experience in in-vitro diagnostics, the company strives to reshape the landscape of global diagnostics, particularly regarding autoimmune diseases and allergies. The MosaiQ and LumiQ brands symbolize AliveDx’s commitment to delivering valuable solutions that enhance diagnostic efficacy and support healthcare providers.
About the MosaiQ Technology
The MosaiQ platform is a state-of-the-art diagnostic tool for testing a range of autoimmune diseases and allergies. Its fully automated and multiplexed microarray system enables complex testing with both high throughput and rapid result delivery, meeting the growing demands for efficiency within laboratory settings.
Contacting AliveDx
For additional details regarding AliveDx and its innovative IVD solutions, interested parties can explore the company's website and connect with AliveDx through their social media channels.
Frequently Asked Questions
What is the MosaiQ AiPlex CD?
The MosaiQ AiPlex CD is a multiplex microarray test designed for the rapid diagnosis of celiac disease.
Why is the 510(k) submission significant?
The 510(k) submission is a step toward gaining FDA approval, allowing the MosaiQ AiPlex CD to be used commercially in the U.S.
What advantages does this assay offer?
This assay offers quick results, a small sample requirement, and simultaneous detection of various markers, enhancing diagnostic accuracy.
How does celiac disease affect patients?
Celiac disease causes an immune response that damages the small intestine when gluten is consumed, leading to multiple health issues.
What is AliveDx's mission?
AliveDx aims to empower diagnostic insights, transform patient care, and innovate solutions for various diagnostics needs, especially in autoimmune conditions.
